Compare Medtronic PLC (MDT) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Victoria's Secret & Co — how do they compare? Medtronic PLC trades at $90.08 (market cap $116.07B), while Victoria's Secret & Co trades at $95.79 (market cap $7.48B). The key difference: Medtronic PLC is far larger — about 15.5× Victoria's Secret & Co's market cap, and Medtronic PLC pays a 3.18% dividend while Victoria's Secret & Co pays none. Which is the better fit depends on your goals.
| MDT | VSXY | |
|---|---|---|
Market Cap | $116.07B | $7.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $105.35 | $99.97 |
52-Week Low | $73.75 | $21.34 |
Enterprise Value | $134.82B | $10.13B |
Dividend Yield | 3.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $89.99, up 0.65% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, 13.2% net income margin, and positive cash flow trends. Recent product innovations including the Hugo robotic surgery platform and AI surgical tools position MDT for growth. Analyst consensus remains strongly positive with 60% buy ratings and $98.75 price target.
MDT presents a compelling investment case with steady revenue growth, dividend aristocrat status, and technological leadership in medical devices. Key risks include increasing debt levels and competitive pressures from Intuitive Surgical. The stock's current valuation at 24.31 P/E appears reasonable given growth prospects, with upside potential to consensus targets if execution continues.
Victoria's Secret (VSXY) trades at $99.97, up 1.45% today and near its 52-week high. The stock shows strong technical momentum with bullish moving averages and positive earnings surprises in three consecutive quarters. Revenue remains stable at $6.23B for 2025, while net income improved to $165M. Analyst consensus is bullish with 55.6% buy ratings and a $110 high price target, supported by recent international expansion success in China and Europe.
VSXY presents growth potential through international expansion and data-driven marketing, but faces valuation concerns with a P/E of 37.5 and competitive retail pressures. The stock's current price exceeds the consensus target, suggesting near-term consolidation risk despite positive technical momentum and improving fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
